Neurocrine Sets Nov. 2 Earnings Call as Medical Chief Returns

Neurocrine Biosciences chose a quiet way to confirm its next earnings date: a short release on Oct. 12 with a schedule, a conference ID and a replay policy. The date, Monday, Nov. 2, is three weeks away. What makes the third-quarter report different from a routine one is the management change that preceded it, since the person who will answer questions about the company’s clinical programs has changed.

The schedule

Neurocrine (Nasdaq: NBIX) will issue its third-quarter 2026 press release on Nov. 2 at 1:00 p.m. Pacific, or 4:00 p.m. Eastern. A conference call and webcast follow at 1:30 p.m. Pacific, or 4:30 p.m. Eastern. The company lists a domestic dial-in number, an international number and the conference ID “NBIX”. The webcast is available through the investors section of neurocrine.com, and a replay will be posted about one hour after the event ends and kept for about a month.

Releasing results 30 minutes before the call is a common pattern for companies that want investors to read the numbers before the discussion begins, and the one-hour replay gives investors in other time zones access the same evening.

A returning medical chief

On Sept. 28 Neurocrine said Eiry W. Roberts, M.D., was returning to its executive team as chief medical officer, effective immediately. She replaces Sanjay Keswani, M.D., who is leaving by mutual agreement. Roberts served as chief medical officer from 2018 to 2025 and then stayed on as a strategic advisor. The company said that in her earlier tenure she led indication-expansion work for INGREZZA and the crinecerfont program, which led to FDA approval of CRENESSITY. Before 2018 she spent 26 years at Eli Lilly and Company, and she sits on the board of Bausch Health Companies.

Chief executive Kyle W. Gano said her knowledge of the pipeline and clinical programs provides continuity while several late-stage programs advance, and he thanked Keswani.

A quarter that follows a change in the chief medical officer is the first chance to hear how the clinical agenda is being described.

What the company sells

The boilerplate in the Oct. 12 notice describes a portfolio of FDA-approved treatments for tardive dyskinesia, chorea associated with Huntington’s disease, classic congenital adrenal hyperplasia, hyperphagia in patients with Prader-Willi syndrome, and endometriosis and uterine fibroids, the last two in collaboration with AbbVie. It also cites a pipeline of compounds in mid- to late-phase development across neurology, psychiatry, endocrinology and immunology.

Another recent release from the company said Neurocrine will present research on Prader-Willi syndrome and real-world experience with VYKAT XR (diazoxide choline) at the Foundation for Prader-Willi Research symposium. The company’s release does not say what the results call will cover, and nothing in the schedule notice itself contains financial information.

Why scheduling notices deserve a read

For a reader who follows biotech and other small and mid-sized issuers, an earnings-date notice is a checkpoint. It confirms that the company is on its usual reporting calendar and gives the exact time of the release relative to the call, which determines when the numbers can be read. The Nov. 2 timing, in the late afternoon Eastern, places the release at the close of the trading day, so the first reaction will come in the following session.

The commercial products to track

The notice names several products indirectly through the conditions they treat. Two product names appear in company announcements around it: INGREZZA, tied to Roberts’ earlier indication-expansion work, and CRENESSITY, which followed from the crinecerfont program. VYKAT XR (diazoxide choline) is the product linked to Prader-Willi syndrome in the symposium release. A reader building a checklist for the call can match each treatment area in the notice to the product the company discusses and ask for the same level of detail on each.

What to watch

On Nov. 2, listeners will want to hear how the company describes its late-stage programs now that Roberts is back, whether management comments on the transition, and how the commercial products listed in the notice are performing. None of those topics is promised in the announcement, and the company has not given financial guidance in it.